Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health
NN9838-8411
Phase 1 other active
Quick answer
Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health for Obesity, CCI, CCI is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Obesity, CCI, CCI
- Phase
- Phase 1
- Modality
- other
- Status
- active